Enzyme

Induced Pluripotent Stem Cells Market Report, Featuring Historical Revenue Data for 2021 and 2022, Estimated Figures for 2023, and Compound Annual Growth Rates (CAGRs) through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Cell, Stem cell, Fibroblast, B cell, Enzyme, Serum, Drug discovery, Row, Good manufacturing practice, Differentiable function, Neuron, GMP, Hepatocyte, Regenerative medicine, Medium (website), Antibody, Drug development, Geography, Astrocyte, IPSC, Endothelium

For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.

Key Points: 
  • For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
  • The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW).
  • The report will provide details with respect to induced pluripotent stem cells.

Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Nanna, DUB, UPS, Therapy, Enzyme, Dub, Ubiquitin, Drug discovery, Pharmaceutical industry

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).

Key Points: 
  • Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).
  • Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.
  • Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for the development of novel therapeutics.
  • Jason Mundin, CEO of Ubiquigent, commented: “We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics.

Oregon Freeze Dry Announces Appointment of New Leader and Organizational Refocus into Food and Life Sciences Verticals

Retrieved on: 
Wednesday, April 3, 2024
E-commerce, Enzyme, Antioxidant, Growth, Apollo, Mars, Incorporated, Probiotic, Astronaut, Blue-collar worker, Flavonoid, Moon, Protein, Walmart, Mickey, NASA, Investment, API, Defense, Meal, Management

ALBANY, Ore., April 3, 2024 /PRNewswire-PRWeb/ -- Oregon Freeze Dry ("OFD" or the "Company"), one of North America's largest and most technologically advanced freeze-dryer of food, probiotics, enzymes, proteins, specialty ingredients, and lyophilized pharmaceutical inputs, announced today its newly restructured business verticals of Food and Life Sciences. With the reorganization, consumer packaged goods industry veteran Craig Mickey has joined the Company as Chief Commercial Officer to lead the Food vertical. OFD Senior Vice President Jeni Billups will become the Chief Commercial Officer of the Life Sciences vertical.

Key Points: 
  • ALBANY, Ore., April 3, 2024 /PRNewswire-PRWeb/ -- Oregon Freeze Dry ("OFD" or the "Company"), one of North America's largest and most technologically advanced freeze-dryer of food, probiotics, enzymes, proteins, specialty ingredients, and lyophilized pharmaceutical inputs, announced today its newly restructured business verticals of Food and Life Sciences.
  • OFD Senior Vice President Jeni Billups will become the Chief Commercial Officer of the Life Sciences vertical.
  • "The new Food and Life Sciences verticals with dedicated leadership and teams will drive focus on the unique needs of each area," said Jim Cohen, CEO of OFD.
  • "With the newly formed Food and Life Sciences verticals with dedicated leadership and teams, we can better drive focus on the unique needs of each area.

Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing

Retrieved on: 
Wednesday, April 3, 2024
Enzyme, Partnership, Business, DNA, Business development, AI, Ginkgo Bioworks, COGS, Ecosystem, API, Fine chemical

NORTHUMBERLAND, England and BOSTON, April 3, 2024 /PRNewswire/ -- Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, Ginkgo and Prozomix aim to build out the production of next generation enzyme plates for active pharmaceutical ingredient (API) manufacturing. This collaboration aims to leverage Ginkgo's Enzyme Services and industry-leading AI/ML models along with Prozomix's existing enzyme libraries and deep experience manufacturing enzyme plates.

Key Points: 
  • Together, Ginkgo and Prozomix aim to build out the production of next generation enzyme plates for active pharmaceutical ingredient (API) manufacturing.
  • This collaboration aims to leverage Ginkgo's Enzyme Services and industry-leading AI/ML models along with Prozomix's existing enzyme libraries and deep experience manufacturing enzyme plates.
  • With Prozomix now in the Technology Network, Ginkgo customers will have access to Prozomix's scalable contract manufacturing services, including enzyme samples from mg to kg scale.
  • Cindy Chang, Senior Director, Business Development at Ginkgo Bioworks: "API manufacturing is poised to greatly benefit from the latest in enzyme engineering and AI/ML enzyme models.

BCC Research Reveals Top Ten Suppliers of Synthetic Biology Technology in 2024

Retrieved on: 
Tuesday, April 2, 2024
Research, Automation, Health, Edit, Enzyme, Growth, Commercialization, Top Ten, Agriculture, Drug discovery, Synthetic biology, Livestock, DNA, Health care, Milk, Food safety, Biofuel, Synthetic, CRISPR, Pharma, Therapy, BCC, Vaccine, Cas9, Food industry

BOSTON, April 2, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Top Ten Suppliers of Synthetic Biology Technology is estimated to increase from $35.5 billion in 2023 to $59.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 10.8% during the forecast period of 2023-2028.

Key Points: 
  • With growing interest and investment from countries worldwide, synthetic biology promises sustainable solutions and transformative applications across industries.
  • Furthermore, it provides forecasts for 2028, allowing stakeholders to anticipate future trends and opportunities in the synthetic biology sector.
  • Growth in Synthetic Biology Foundries: Synthetic biology foundries serve as collaborative hubs for research and development, providing access to shared resources, expertise, and standardized biological parts.
  • Increasing Research and Development Investment by Pharma Companies: Pharmaceutical companies are increasingly recognizing the potential of synthetic biology and investing in research and development efforts.

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Retrieved on: 
Tuesday, April 2, 2024
Health, Interdisciplinarity, Enzyme, Cell, Neoplasm, Research, Science, Cancer, University, Biology, MicroRNA, Chemistry, Therapy, NK, Pharmaceutical industry

WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award.

Key Points: 
  • WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award.
  • This prestigious award honors outstanding individuals whose scholarly commitments and contributions to research have significantly advanced their respective fields.
  • Deiters' peers described him as "one of the most productive research contributors in the field" whose research program "shows both breadth and depth."
  • "We commend Deiters for his outstanding dedication and invaluable contributions to the development of SNAP-CAR T technology," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Retrieved on: 
Thursday, March 28, 2024
Partnership, HTP, Prednisolone, Enzyme, DNA, Hydrocortisone, Budesonide, Willow, Fine chemical

Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.

Key Points: 
  • Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.
  • Commercial revenue is expected to be potentially milestone, royalty, and ingredient supply revenue.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.
  • In addition, commercial stage revenue is expected to commence on multiple programs.

Curie Co Launches Curamina™, a Naturally-Derived Bioactive For Bond Building

Retrieved on: 
Tuesday, March 26, 2024
Skin care, Protein, Biology, Enzyme, Textile, Skin, Collagen, Tanning (leather)

DURHAM, N.C., March 26, 2024 /PRNewswire-PRWeb/ -- Curie Co Inc. today announced the launch of Curamina, a naturally derived bioactive bond builder for the proteins that drive personal care and fashion. Curamina mimics the protein bond building function of enzymes already present in the skin and hair providing a natural alternative to chemical crosslinkers. Whether it's unlocking superior smoothing and strengthening benefits in hair care or providing a gentle skin conditioning solution in skincare, this bioactive unlocks performance without compromise. Curamina forms new peptide bonds to collagen and keratin and has been demonstrated to outperform legacy petrochemical ingredients like formaldehyde to the benefit of people and the planet.

Key Points: 
  • The proprietary bioactive powers sustainable, higher-performance products in hair care and skin care with elegant biology
    DURHAM, N.C., March 26, 2024 /PRNewswire-PRWeb/ -- Curie Co Inc .
  • today announced the launch of Curamina, a naturally derived bioactive bond builder for the proteins that drive personal care and fashion.
  • Curamina mimics the protein bond building function of enzymes already present in the skin and hair providing a natural alternative to chemical crosslinkers.
  • Whether it's unlocking superior smoothing and strengthening benefits in hair care or providing a gentle skin conditioning solution in skincare, this bioactive unlocks performance without compromise.

Enzymedica Showcases Groundbreaking Papaya Enzyme Products and More at Natural Products Expo West 2024

Retrieved on: 
Thursday, March 21, 2024
Enzyme, Expo, Gummy candy, Science, Probiotic, Dietary fiber, Fasting, Food, Gold, Marketing

ANAHEIM, Calif., March 21, 2024 /PRNewswire/ -- Enzymedica , a leading provider of natural digestive health supplements, proudly participated in Natural Products Expo West 2024, the preeminent event for the natural, organic and healthy products industry.

Key Points: 
  • ANAHEIM, Calif., March 21, 2024 /PRNewswire/ -- Enzymedica , a leading provider of natural digestive health supplements, proudly participated in Natural Products Expo West 2024, the preeminent event for the natural, organic and healthy products industry.
  • Natural Products Expo West is renowned for its expansive showcase of the latest in food and beverage, clean beauty and home products, and supplements and ingredients.
  • Enzymedica took full advantage of this vibrant setting to launch two groundbreaking papaya enzyme products: Papaya Complete and Papaya Gold.
  • The company's presence at Expo underscores its dedication to innovation and excellence in the natural products industry.

AspenClean Wins Better Homes & Garden's Clean House Awards For The Third Year in a Row

Retrieved on: 
Friday, March 15, 2024
Chlorine, Health, Enzyme, Phosphate, Better Homes, EWG, Detergent, Mineral, House, Better Homes and Gardens, Plant, Skin, Bleach, Allergy, Multimedia, Clean House

"We are so proud to be recognized once again by Better Homes & Gardens and we deeply admire the Clean House Awards' commitment to sustainability in our industry," said AspenClean co-CEO Alicia Sokolowski. "Since day one, our primary goal has been to prioritize health and environmental protection by offering natural alternatives to toxic cleaning supplies. This year's winners -- Oxygen Bleach Powder and Dish Soap Refill -- are two of our customers' favorites and reflect our shared passion for a cleaner, greener future."

Key Points: 
  • For the third year in a row, AspenClean's plant-based, EWG VERIFIED®, and all-natural cleaning products have been selected as winners of the coveted Clean House Awards presented by Dotdash Meredith's Better Homes & Gardens.
  • NEW YORK, March 15, 2024 /PRNewswire-PRWeb/ -- For the third year in a row, AspenClean's plant-based, EWG VERIFIED®, and all-natural cleaning products have been selected as winners of the coveted Clean House Awards presented by Dotdash Meredith's Better Homes & Gardens.
  • "We are so proud to be recognized once again by Better Homes & Gardens and we deeply admire the Clean House Awards' commitment to sustainability in our industry," said AspenClean co-CEO Alicia Sokolowski.
  • The Better Homes & Gardens 2024 Clean House Awards are featured online and in the April issue, available on newsstands March 22nd.